Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
Exceeds 3Q 2025 Guidance for Total DuPont Raises FY 2025 Earnings Guidance for New DuPont Announces $2 Billion Share Repurchase Authorization, $500 ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback